6.00 0.00 (0.00%)
After hours: 4:40PM EDT
|Bid||6.00 x 1300|
|Ask||6.60 x 1200|
|Day's Range||5.99 - 6.34|
|52 Week Range||3.60 - 9.76|
|Beta (3Y Monthly)||1.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||35.00|
A look at the shareholders of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) can tell us which group is most powerful...
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really...
-- Edasalonexent Global Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Is Enrolling Rapidly --
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced the appointment of Hugh M. Cole to its Board of Directors. Mr. Cole has more than 20 years of pharmaceutical business development experience and is currently the Chief Business Officer and Head of Corporate Development at Jounce Therapeutics. “We are pleased to have Hugh join us on the Board,” said Ken Bate, Chairman of Catabasis’ Board of Directors.
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, August 13, 2019 at 4:15pm ET at the Parker New York in New York, NY.
Jill Milne became the CEO of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) in 2008. This analysis aims first to...
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, shared an update on the clinical development of edasalonexent, a novel NF-kB inhibitor for the treatment of Duchenne muscular dystrophy (DMD) this week at the Parent Project Muscular Dystrophy (PPMD) 25th Annual Conference. Screening is ongoing for the randomized, double-blind, placebo-controlled trial in the United States, Canada, Australia, the United Kingdom, Ireland, Sweden, Germany and Israel and making strong progress. Clinical trial sites globally are enrolling quickly and sites in the United Kingdom, Ireland, Sweden, Germany and Israel are at capacity and no longer accepting additional patients.
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today presented new preclinical data showing preserved bone health with edasalonexent in contrast to negative effects of the corticosteroid prednisolone in a mouse model of Duchenne muscular dystrophy (DMD). Edasalonexent is a novel NF-kB inhibitor in Phase 3 development for the treatment of DMD. The data were presented at the Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy.
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent, a novel NF-kB inhibitor in Phase 3 development for the treatment of Duchenne muscular dystrophy , at two upcoming meetings: the Symposium on Muscle-Bone Interaction in Duchenne Muscular Dystrophy and the Parent Project Muscular Dystrophy 25th Annual Conference.
Vertex (VRTX) is expanding its gene editing pipeline into new disease areas by expanding collaboration with CRISPR Therapeutics and acquiring Exonics.
Boston, MA, based Investment company SV Life Sciences Advisers, LLC buys Catabasis Pharmaceuticals Inc, sells KalVista Pharmaceuticals Inc, Avrobio Inc during the 3-months ended 2019Q1, according to the ...
-- Edasalonexent Phase 3 PolarisDMD Trial in Duchenne Muscular Dystrophy Enrolling Boys Globally --
Catabasis Pharmaceuticals, Inc. (CATB), a clinical-stage biopharmaceutical company, today announced that it will present data on edasalonexent treatment in boys affected by Duchenne muscular dystrophy (DMD) from the MoveDMD trial open-label extension at the American Academy of Neurology 71st Annual Meeting to be held May 4 to May 10, 2019 in Philadelphia, PA. Richard Finkel, M.D., Chief, Division of Neurology, Department of Pediatrics at Nemours Children’s Health System and a Principal Investigator for the Phase 2 MoveDMD and Phase 3 PolarisDMD studies of edasalonexent, will give an oral presentation titled “Edasalonexent, an NF-kB Inhibitor, Slows Longer-Term Disease Progression on Multiple Functional and MRI Assessments Compared to Control Period in 4 to 7 Year-Old Patients with Duchenne Muscular Dystrophy” during the S51 session “Child Neurology: Bench to Bedside: Progress in Treating Genetic Disorders” on Thursday, May 9 at 4:25pm ET.
Anyone researching Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of...
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that it will present edasalonexent program data, including from the Phase 2 MoveDMD trial and open-label extension, and the design of the Phase 3 PolarisDMD trial, at two major medical meetings in April: the 12th UK Neuromuscular Translational Research Conference and the 2019 Muscular Dystrophy Association ...
Proteostasis (PTI) announces data from a phase I study evaluating its triplet combination in cystic fibrosis. Although data were promising, it was weaker than rival Vertex's triplet combinations.